Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1959 1
1962 1
1964 2
1965 1
1966 3
1967 6
1968 3
1969 3
1970 3
1971 3
1972 2
1974 1
1975 3
1976 3
1977 2
1978 14
1979 6
1980 6
1981 3
1982 13
1983 16
1984 17
1985 16
1986 12
1987 16
1988 18
1989 16
1990 21
1991 24
1992 19
1993 19
1994 24
1995 19
1996 33
1997 41
1998 44
1999 37
2000 28
2001 45
2002 41
2003 39
2004 35
2005 47
2006 41
2007 44
2008 55
2009 53
2010 43
2011 58
2012 80
2013 88
2014 63
2015 60
2016 74
2017 77
2018 59
2019 66
2020 79
2021 81
2022 74
2023 34

Text availability

Article attribute

Article type

Publication date

Search Results

1,702 results

Results by year

Filters applied: . Clear all
Page 1
Recent Advances in the Treatment of Colorectal Cancer: A Review.
Shinji S, Yamada T, Matsuda A, Sonoda H, Ohta R, Iwai T, Takeda K, Yonaga K, Masuda Y, Yoshida H. Shinji S, et al. Among authors: matsuda a. J Nippon Med Sch. 2022 Jun 28;89(3):246-254. doi: 10.1272/jnms.JNMS.2022_89-310. Epub 2022 Jan 25. J Nippon Med Sch. 2022. PMID: 35082204 Free article. Review.
Application of moisturizer to neonates prevents development of atopic dermatitis.
Horimukai K, Morita K, Narita M, Kondo M, Kitazawa H, Nozaki M, Shigematsu Y, Yoshida K, Niizeki H, Motomura K, Sago H, Takimoto T, Inoue E, Kamemura N, Kido H, Hisatsune J, Sugai M, Murota H, Katayama I, Sasaki T, Amagai M, Morita H, Matsuda A, Matsumoto K, Saito H, Ohya Y. Horimukai K, et al. Among authors: matsuda a. J Allergy Clin Immunol. 2014 Oct;134(4):824-830.e6. doi: 10.1016/j.jaci.2014.07.060. J Allergy Clin Immunol. 2014. PMID: 25282564 Free article. Clinical Trial.
Efficacy and safety of romiplostim in refractory aplastic anaemia: a Phase II/III, multicentre, open-label study.
Jang JH, Tomiyama Y, Miyazaki K, Nagafuji K, Usuki K, Uoshima N, Fujisaki T, Kosugi H, Matsumura I, Sasaki K, Kizaki M, Sawa M, Hidaka M, Kobayashi N, Ichikawa S, Yonemura Y, Enokitani K, Matsuda A, Ozawa K, Mitani K, Lee JW, Nakao S. Jang JH, et al. Among authors: matsuda a. Br J Haematol. 2021 Jan;192(1):190-199. doi: 10.1111/bjh.17190. Epub 2020 Nov 5. Br J Haematol. 2021. PMID: 33152120 Free PMC article. Clinical Trial.
Neuroimmune interactions in allergic diseases.
Matsuda A. Matsuda A. Allergol Int. 2022 Jul;71(3):263-264. doi: 10.1016/j.alit.2022.05.004. Epub 2022 Jun 9. Allergol Int. 2022. PMID: 35690532 Free article. No abstract available.
Combination of TAS-102 and bevacizumab as third-line treatment for metastatic colorectal cancer: TAS-CC3 study.
Yoshida Y, Yamada T, Kamiyama H, Kosugi C, Ishibashi K, Yoshida H, Ishida H, Yamaguchi S, Kuramochi H, Fukazawa A, Sonoda H, Yoshimatsu K, Matsuda A, Hasegawa S, Sakamoto K, Otsuka T, Koda K; TAS CC3 Study Group.. Yoshida Y, et al. Among authors: matsuda a. Int J Clin Oncol. 2021 Jan;26(1):111-117. doi: 10.1007/s10147-020-01794-8. Epub 2020 Oct 21. Int J Clin Oncol. 2021. PMID: 33083913 Clinical Trial.
Beyond starving cancer: anti-angiogenic therapy.
Hida K, Maishi N, Matsuda A, Yu L. Hida K, et al. Among authors: matsuda a. J Med Ultrason (2001). 2023 May 12. doi: 10.1007/s10396-023-01310-1. Online ahead of print. J Med Ultrason (2001). 2023. PMID: 37170042 Review.
Human eosinophils constitutively express a unique serine protease, PRSS33.
Toyama S, Okada N, Matsuda A, Morita H, Saito H, Fujisawa T, Nakae S, Karasuyama H, Matsumoto K. Toyama S, et al. Among authors: matsuda a. Allergol Int. 2017 Jul;66(3):463-471. doi: 10.1016/j.alit.2017.01.001. Epub 2017 Feb 16. Allergol Int. 2017. PMID: 28216055 Free article.
Biweekly TAS-102 and bevacizumab as third-line chemotherapy for advanced or recurrent colorectal cancer: a phase II, multicenter, clinical trial (TAS-CC4 study).
Matsuoka H, Yamada T, Ohta R, Yoshida Y, Watanabe T, Takahashi M, Kosugi C, Fukazawa A, Kuramochi H, Matsuda A, Sonoda H, Yoshida H, Hasegawa S, Sakamoto K, Otsuka T, Hirata K, Koda K; TAS CC4 Study Group. Matsuoka H, et al. Among authors: matsuda a. Int J Clin Oncol. 2022 Dec;27(12):1859-1866. doi: 10.1007/s10147-022-02243-4. Epub 2022 Oct 6. Int J Clin Oncol. 2022. PMID: 36201089 Clinical Trial.
1,702 results